Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site

[1]  G. Konjević,et al.  In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients , 2010, Melanoma research.

[2]  D. Rigel,et al.  The Evolution of Melanoma Diagnosis: 25 Years Beyond the ABCDs , 2010, CA: a cancer journal for clinicians.

[3]  P. Rutkowski,et al.  Melanoma without a Detectable Primary Site with Metastases to Lymph Nodes , 2010, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[4]  J. Coebergh,et al.  Epidemiology of Extracutaneous Melanoma in the Netherlands , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[5]  Jeffrey E Gershenwald,et al.  Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Gershenwald,et al.  2010 TNM Staging System for Cutaneous Melanoma…and Beyond , 2010, Annals of Surgical Oncology.

[7]  P. G. Lang,et al.  Dermoscopy of fully regressive cutaneous melanoma , 2009 .

[8]  A. Hauschild,et al.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2008, The Lancet.

[9]  D. Morton,et al.  Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Eggermont,et al.  Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  D. Jukic,et al.  Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Jeffrey E. Lee,et al.  Metastatic melanoma to lymph nodes in patients with unknown primary sites , 2006, Cancer.

[13]  A. Eggermont,et al.  Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial , 2005, The Lancet.

[14]  D. Schadendorf,et al.  Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Eggermont,et al.  Prognostic factors after cervical lymph node dissection for cutaneous melanoma metastases , 2005, Melanoma research.

[16]  F. Hodi,et al.  Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute , 2005, Melanoma research.

[17]  J. Wolchok,et al.  Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity , 2003, Oncogene.

[18]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Thomas,et al.  Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma , 2000, The British journal of surgery.

[20]  D. Morton,et al.  Cytoreductive surgery and adjuvant immunotherapy: A new management paradigm for metastatic melanoma , 1999, CA: a cancer journal for clinicians.

[21]  L. Karnell,et al.  The National Cancer Data Base report on cutaneous and noncutaneous melanoma , 1998, Cancer.

[22]  A. Halpern,et al.  Melanoma of unknown primary site , 1997, Cancer.